.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,133,893

« Back to Dashboard

Claims for Patent: 8,133,893

Title:Trazodone and trazodone hydrochloride in purified form
Abstract: A process of production of trazodone or trazodone hydrochloride that comprises the steps of: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40.degree. C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. ##STR00001##
Inventor(s): Marchetti; Marcello (Rome, IT), Iacoangeli; Tommaso (Rome, IT), Ciottoli; Giovanni Battista (Rome, IT), Biondi; Giuseppe (Castel Gandolfo, IT)
Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (Rome, IT)
Application Number:12/513,048
Patent Claims: 1. Trazodone or trazodone hydrochloride, wherein alkylating substances are present in a total amount which is less than 15 ppm and said alkylating substances are selected from the group consisting of 2,2-dichloroethylamine, 1-bromo-3-chloro-propane, N-(3-chlorophenyl)-N'-(3-chloropropyl)-piperazine, 2-(3-chloropropyl)-s-triazolo-[4,3-a]-pyridin-3-one, 3-chloro-N,N'-dichloroethyl-aniline, 2-{3-[bis-(2-chloroethyl)-amino]-propyl}-2H-[1,2,4]-triazolo[4,3-a]pyridi- n-3-one, 2,2-dibromoethylamine, 1,3-dichloropropane and a mixture thereof.

2. Trazodone or trazodone hydrochloride according to claim 1, which comprises less than 10 ppm of said alkylating substances.

3. Trazodone or trazodone hydrochloride according to claim 1, which comprises less than 2.5 ppm of said alkylating substances.

4. Trazodone or trazodone hydrochloride according to claim 1, wherein said alkylating substances are selected from the group consisting of 2,2-dichloroethylamine, 1-bromo-3-chloro-propane, N-(3-chlorophenyl)-N'-(3-chloropropyl)-piperazine, and a mixture thereof.

5. Trazodone or trazodone hydrochloride according to claim 1, which comprises less than 1 ppm of each of said alkylating substances.

6. Trazodone or trazodone hydrochloride according to claim 5, wherein said alkylating substances are selected from the group consisting of 2,2-dichloroethylamine, 1-bromo-3-chloropropane, N-(3-chlorophenyl)-N'-(3-chloropropyl)-piperazine, 2-(3-chloropropyl)-s-triazolo-[4,3-a]-pyridin-3-one, 3-chloro-N,N'-dichloroethylaniline, 2-{3-[bis-(2-chloroethyl)-amino]-propyl}-2H-[1,2,4]-triazolo[4,3-a]pyridi- n-3-one, and 2,2-dibromoethylamine.

7. Trazodone or trazodone hydrochloride according to claim 5, wherein said alkylating substances are selected from the group consisting of 2,2-dichloroethylamine, 1-bromo-3-chloro-propane, and N-(3-chlorophenyl)-N'-(3-chloropropyl)-piperazine.

8. A pharmaceutical composition, comprising trazodone hydrochloride according to claim 1 and at least one pharmaceutically acceptable excipient.

9. A process for producing trazodone or trazodone hydrochloride according to claim 1, which comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40.degree. C. for at least 30 minutes; (e) recovering said trazodone; and (f) optionally, treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride, wherein said trazodone or trazodone hydrochloride comprises less than 15 ppm of alkylating substances.

10. A process according to claim 9, wherein said trazodone or trazodone hydrochloride comprises less than 10 ppm of alkylating substances.

11. A process according to claim 9, wherein said trazodone or trazodone hydrochloride comprises less than 2.5 ppm of alkylating substances.

12. A process according to claim 9, wherein said trazodone or trazodone hydrochloride comprises less than 1 ppm of alkylating substances.

13. A process according to claim 9, wherein said organic solvent is selected from the group consisting of an alcohol, an ether, a hydrocarbon, a ketone, and an ester.

14. A process according to claim 13, wherein said organic solvent is selected from the group consisting of ethyl alcohol, propyl alcohol, isobutyl alcohol, hexyl alcohol, benzyl alcohol, ethyl ether, propyl ether, toluene, benzene, xylene, acetone, methyl ethyl ketone, methyl isobutyl ketone, and ethyl acetate.

15. A process according to claim 9, wherein said organic phase comprises an amount of trazodone in the range from 10 g to 50 g per 100 grams of organic phase.

16. A process according to claim 9, wherein said aqueous phase comprises at least one basic compound selected from the group consisting of at least one inorganic base, at least one organic base, or mixtures thereof.

17. A process according to claim 16, wherein said inorganic base is selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium phosphate, potassium phosphate, ammonium hydroxide, magnesium oxide, hydrazine, and hydroxylamine.

18. A process according to claim 16, wherein said organic base is selected from the group consisting of an aliphatic amine and an aromatic amine.

19. A process according to claim 9, wherein said basic compound is added in an amount in the range from 0.05 to 1 mol per mole of trazodone.

20. A process according to claim 9, wherein said aqueous phase is added in an amount in the range from 30 g to 100 g per 100 grams of organic phase.

21. A process according to claim 9, wherein said aqueous phase comprises a phase transfer catalyst.

22. A process according to claim 21, wherein said phase transfer catalyst is selected from the group consisting of a quaternary ammonium salt and a quaternary phosphonium salt.

23. A process according to claim 22, wherein said quaternary ammonium salt is selected from the group consisting of benzyl tributyl ammonium bromide, benzyl tributyl ammonium chloride, benzyl triethyl ammonium bromide, benzyl triethyl ammonium chloride, benzyl trimethyl ammonium chloride, cetyl pyridinium bromide, cetyl pyridinium chloride, cetyl trimethyl ammonium bromide, didecyl dimethyl ammonium chloride, dodecyl trimethyl ammonium bromide, dodecyl trimethyl ammonium chloride, methyl tributyl ammonium chloride, methyl tributyl ammonium hydrogen sulphate, methyl tricaprilyl ammonium chloride, methyl trioctyl ammonium chloride, phenyl trimethyl ammonium chloride, tetrabutyl ammonium borohydride, tetrabutyl ammonium bromide, tetrabutyl ammonium chloride, tetrabutyl ammonium fluoride, tetrabutyl ammonium hydrogen sulphate, tetrabutyl ammonium hydroxide, tetrabutyl ammonium iodide, tetrabutyl ammonium perchlorate, tetraethyl ammonium bromide, tetraethyl ammonium chloride, tetraethyl ammonium hydroxide, tetrahexyl ammonium bromide, tetrahexyl ammonium iodide, tetramethyl ammonium bromide, tetramethyl ammonium chloride, tetramethyl ammonium fluoride, tetramethyl ammonium hydroxide, tetramethyl ammonium iodide, tetraoctyl ammonium bromide, tetrapropyl ammonium bromide, tetrapropyl ammonium chloride, tetrapropyl ammonium hydroxide, tributyl methyl ammonium chloride, and triethyl benzyl ammonium chloride.

24. A process according to claim 22, wherein said quaternary ammonium salt is selected from the group consisting of tetrabutyl ammonium bromide, tetrabutyl ammonium chloride, benzyl triethyl ammonium bromide, benzyl triethyl ammonium chloride, benzyl trimethyl ammonium chloride, benzyl trimethyl ammonium bromide, benzyl tributyl ammonium bromide, and benzyl tributyl ammonium chloride.

25. A process according to claim 22, wherein said quaternary phosphonium salt is selected from the group consisting of benzyl triphenyl phosphonium bromide, benzyl triphenyl phosphonium chloride, butyl triphenyl phosphonium bromide, butyl triphenyl phosphonium chloride, ethyl triphenyl phosphonium acetate, ethyl triphenyl phosphonium bromide, ethyl triphenyl phosphonium iodide, hexadecyl tributyl phosphonium bromide, methyl triphenyl phosphonium bromide, tetrabutyl phosphonium bromide, and tetraphenyl phosphonium bromide.

26. A process according to claim 22, wherein said aqueous phase comprises an amount of phase transfer catalyst in the range from 0.05 g to 0.5 g per 100 grams of aqueous phase.

27. A process according to claim 9, wherein said heating step (d) is carried out at a temperature between 40.degree. C. and the boiling point of the mixture of organic phase and aqueous phase, for a period of time between 30 minutes and 300 minutes.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc